Soluble interleukin-2 receptor [sIL-2R] as a tumor marker in hematologic malignancies
New Egyptian Journal of Medicine [The]. 1997; 16 (4): 352-358
en Inglés
| IMEMR
| ID: emr-46217
ABSTRACT
This work aimed to evaluate serum levels of sIL-2R in some of the hematologic malignancies and to find out if it could be a predictive marker of tumor burden and response to therapy. The mean value of sIL-2R in patients with acute lymphoblastic leukemia [ALL] was significantly higher than the controls. It was also significantly high in the patients with activity as compared with those at remission. Patients with chronic lymphocytic leukemia [CLL] had significantly elevated sIL-2R compared with the controls. The mean value of sIL-2R in the newly diagnosed cases of CLL was significantly higher than that of the group under treatment. There was no significant difference in the mean value of sIL-2R on comparing patients with stage I CLL to those with stage II. There was a significant difference between patients with stage I CLL and those with stage IV and between patients with stage II and stage IV. Newly diagnosed cases had a significantly high mean serum value of sIL-2R compared with those under treatment. Also, patients under treatment showed a significantly high mean serum value of sIL-2R compared with those at remission. Thus, it is clear that measurements of serum sIL-2R in patients with ALL, CLL, non-Hodgkin's lymphoma [NHL] and Hodgkin's lymphoma [HL] could offer a useful marker for tumor burden, prognosis and monitoring of treatment
Buscar en Google
Índice:
IMEMR (Mediterraneo Oriental)
Asunto principal:
Linfoma no Hodgkin
/
Enfermedad de Hodgkin
/
Leucemia Linfocítica Crónica de Células B
/
Biomarcadores de Tumor
/
Interleucina-2
/
Leucemia-Linfoma Linfoblástico de Células Precursoras
Límite:
Femenino
/
Humanos
/
Masculino
Idioma:
Inglés
Revista:
New Egypt. J. Med.
Año:
1997
Similares
MEDLINE
...
LILACS
LIS